Análisis Argos
FUL
FULCara
H.B. Fuller Company · Basic Materials
US$ 57.11
precio al 2026-07-28
Valor justo Argos*
US$ 31–36
vs. su valor justo
74% por encima
Score Argos
61/100
LA RESPUESTA
El mercado le pide crezca 21.3% al año — más de lo que ha demostrado (2.8%). Estás pagando un futuro que todavía no probó: el margen de error es mínimo.
Recompensas
✓Cotiza 28% por debajo de su valor justo.
✓Las ganancias crecieron 17% el último año.
Riesgos
!El precio pide más crecimiento del que la empresa ha demostrado.
!Balance frágil: la deuda pesa sobre el negocio.
!Crecimiento estancado o en baja.
VALOR1/6FUTURO2/6PASADO3/6SALUD2/6DIVIDENDO4/6
El Iris de calidad
VALOR1/6FUTURO2/6PASADO3/6SALUD2/6DIVIDENDO4/6
ValorCotiza por encima de su valor justo
FuturoCrecimiento moderado
PasadoHistorial aceptable
SaludBalance razonable
DividendoDevuelve capital al accionista
Score Argos61de 100Cara
Ingresos▼3%
US$ 3.5 B
Margen operativo▲12%
11.5%
Flujo de caja libre▼25%
US$ 0.1 B
Deuda neta
US$ 1.9 B
Lo esencial, sin ruido
Cap. de mercadoUS$ 3.1B
P/E20.2x
EV/EBITDA8.6x
FCF yield3.9%
ROIC7.1%
Margen operativo11.5%
Crecim. ingresos-2.7%/año
Piotroski F7/9
Competidores

Los rivales, con el mismo ojo

El Iris de calidad de cada competidor, lado a lado. Tocá uno para ver su análisis.

Novedades

Noticias recientes

zacks.com · 10 jul
Should Value Investors Buy H. B. Fuller (FUL) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
zacks.com · 9 jul
FUL Stock Is Riding Medical, Aerospace and Pricing Trends
FUL is tapping medical, aerospace and pricing trends to support margins, but volume weakness still clouds its path to stronger growth.
zacks.com · 9 jul
Is FUL Stock a Buy Now or a Value Trap for Cautious Investors?
FUL trades near the low end of its five-year valuation range as improving earnings meet volume, inflation and leverage risks tied to its medical-market expansion.
zacks.com · 9 jul
H.B. Fuller Stock Outlook Hinges on Margins, Mix and M&A
FUL's outlook rests on pricing, margins and portfolio reshaping as medical expansion and M&A aim to offset uneven demand across key end markets.
zacks.com · 6 jul
FUL vs. PPG: Which Stock Is the Better Value Option?
Investors interested in stocks from the Chemical - Specialty sector have probably already heard of H. B. Fuller (FUL) and PPG Industries (PPG).
zacks.com · 30 jun
H.B. Fuller Q2 Earnings Call Flags Pricing, AMS Ambitions
FUL flags stronger pricing, higher profit guidance and a proposed AMS deal aimed at expanding its medical adhesives platform and boosting margins.
seekingalpha.com · 26 jun
H.B. Fuller: Overreaction, Or Proof Of Slowdown
H.B. Fuller is rated a "buy" with a conservative $80/share price target, reflecting improved fundamentals and recent M&A. FUL's recent results validate earnings recovery: near-6% revenue growth, ~20% AEPS improvement, double-digit EBITDA gains, and record operating cash flow. The AMS acquisition is expected to drive margin expansion, higher-quality revenue, and meaningful revenue and cost synergies, supporting long-term profitability.
seekingalpha.com · 25 jun
H.B. Fuller Company (FUL) Q2 2026 Earnings Call Transcript
H.B. Fuller Company (FUL) Q2 2026 Earnings Call Transcript

* Valor justo Argos: estimación educativa del valor intrínseco según el propio flujo de caja de la empresa y su capacidad de crecimiento — no un precio objetivo ni una recomendación. Esto es información y educación, no asesoría de inversión. Rendimiento pasado no garantiza resultados futuros.